Other studies in NSCLC have also shown that FGFR2 inhibition drives the expansion of T-cell clones while reducing other immunosuppressive cell subtypes to support enhanced antitumor immunity.37 This evidence concerns the gene FGFR2 and non-small cell lung carcinoma.